Načítá se...
Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone
Prednisone is typically co-administered with abiraterone in treatment of castrate resistant prostate cancer to prevent toxicities of secondary mineralocorticoid excess. However, many patients do not desire or cannot tolerate chronic glucocorticoid therapy. In this retrospective study, we report that...
Uloženo v:
| Vydáno v: | Clin Genitourin Cancer |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501307/ https://ncbi.nlm.nih.gov/pubmed/28131750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.12.008 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|